3 Two Hospital Networks and a Portable Molecular Testing Maker Stocks With a Strong Future Roadmap: Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics

Hospital and molecular testing stocks let investors follow the companies that treat patients in hospitals and the companies that make the tests that guide treatment. Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics cover two large hospital networks and a maker of portable molecular testing systems.

This list covers three hospital and molecular testing stocks with complete current figures: Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital and Molecular Testing Stocks?

Hospital and molecular testing stocks are listed companies that run hospitals or supply the diagnostic systems used in patient care. Their earnings depend on bed capacity, occupancy, revenue per bed and the volume of tests sold.

Hospital and Molecular Testing Stocks at a Glance

On valuation, Fortis Healthcare and Max Healthcare Institute trade at a P/E below the industry P/E, while Molbio Diagnostics trades above it, which reflects the growth the market already expects. Readers comparing hospital and molecular testing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital and molecular testing stocks can use the coming numbers to test whether growth is holding.

Why Do Hospital and Molecular Testing Stocks Have a Strong Roadmap in India?

Hospital and molecular testing stocks have a strong roadmap in India because demand for advanced treatment and early testing is growing faster than the supply of organised hospital beds and point of care diagnostics.

• Rising health spending. Higher incomes and insurance cover bring more patients to organised hospitals.
• Capacity additions. New beds in proven cities raise admissions and procedure volumes.
• Testing at the point of care. Portable molecular systems extend lab-grade results to smaller centres.

Why Fortis Healthcare Features Among These Hospital and Molecular Testing Stocks

Among the hospital and molecular testing stocks on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.

Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%.

In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.

Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

What to watch: Track bed additions, occupancy and revenue per occupied bed.

Why Max Healthcare Institute Features Among These Hospital and Molecular Testing Stocks

Among the multi-specialty hospital shares on this list, Max Healthcare Institute runs a large network of multi-specialty hospitals concentrated in Delhi NCR, Punjab, Uttarakhand and Maharashtra, with a strong presence in oncology, cardiac sciences, neurosciences and orthopaedics.

In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%.

Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P/E of 55.4, below the industry P/E of 59.6.

Roadmap: The roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.

What to watch: Track how quickly new beds reach stable occupancy and whether average revenue per occupied bed keeps rising.

Why Molbio Diagnostics Features Among These Hospital and Molecular Testing Stocks

Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.

The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.

Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.

Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.

Fortis Healthcare vs Max Healthcare Institute vs Molbio Diagnostics on Key Financials

The table below sets the three hospital and molecular testing stocks side by side on revenue, profit and margin, using reported figures.

Molbio Diagnostics posts the highest return on equity in this group at 14.2%. Fortis Healthcare has the largest FY26 revenue at Rs 9,178 crore, and Max Healthcare Institute shows the fastest revenue growth with a 20.4% compound annual rate. A useful habit with hospital and molecular testing stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Hospital and Molecular Testing Stocks

Every theme carries risks that deserve a check before any decision. For these hospital and molecular testing stocks, the main points are: Long-term multi-specialty hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Ramp-up timing. New hospital wings take time to reach stable occupancy.
• Doctor availability. Specialist doctors are central to growth and hard to attract.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital and molecular testing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital and Molecular Testing Stocks

Hospital and molecular testing stocks reward investors who follow bed additions, occupancy and test volumes together. Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics each have a clear expansion path. Based on the 20 October 2026 close, Fortis Healthcare trades at Rs 737.8, Max Healthcare Institute at Rs 830 and Molbio Diagnostics at Rs 1,434.8. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these hospital and molecular testing stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track hospital and molecular testing stocks, set price alerts and get research-backed stock ideas.

What are hospital and molecular testing stocks?

Ans. Hospital and molecular testing stocks are listed companies that run hospitals or supply the diagnostic systems used in patient care. Their earnings depend on bed capacity, occupancy, revenue per bed and the volume of tests sold. This list looks at three of them, Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which hospital and molecular testing stocks are covered in this list?

Ans. This list covers Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics. Based on the 20 October 2026 close, Fortis Healthcare traded at Rs 737.8, Max Healthcare Institute at Rs 830 and Molbio Diagnostics at Rs 1,434.8. Their return on equity ranges from 10.5% to 14.2%, and their revenue compound annual growth from FY22 to FY26 ranges from 12.4% to 20.4%.

Why do hospital and molecular testing stocks have a strong future roadmap in India?

Ans. Hospital and molecular testing stocks have a strong roadmap in India because demand for advanced treatment and early testing is growing faster than the supply of organised hospital beds and point of care diagnostics. The main drivers are as follows. Rising health spending. Higher incomes and insurance cover bring more patients to organised hospitals. Capacity additions. New beds in proven cities raise admissions and procedure volumes. Testing at the point of care. Portable molecular systems extend lab-grade results to smaller centres. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Fortis Healthcare performed financially?

Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.

How has Max Healthcare Institute performed financially?

Ans. Revenue rose from Rs 4,059 crore in FY22 to Rs 8,536 crore in FY26, a compound annual growth rate of 20.4%. Net profit grew from Rs 605 crore in FY22 to Rs 1,442 crore in FY26, which works out to a compound annual growth rate of 24.3%. In the June 2026 quarter, revenue grew 16.6% year on year to Rs 2,407 crore, while net profit rose 4.9% to Rs 323 crore. The company has a return on equity of 13.4%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 80,717 crore. The stock trades at a P/E of 55.4, below the industry P/E of 59.6. Looking ahead, the roadmap rests on adding beds through brownfield expansion at existing campuses and through new hospitals in cities where the group already has referral strength. Higher bed occupancy and a richer case mix lift revenue per occupied bed, which is the number hospital analysts follow most closely.

How has Molbio Diagnostics performed financially?

Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.

What risks should investors check before buying hospital and molecular testing stocks?

Ans. Investors should check a few risks before buying hospital and molecular testing stocks. Ramp-up timing. New hospital wings take time to reach stable occupancy. Doctor availability. Specialist doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital and molecular testing stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.